Pharmacogenomic Analysis of CYP3A5*3 and Tacrolimus Trough Concentrations in Vietnamese Renal Transplant Outcomes

References

• Nguyen TVA, Nguyen HD, Nguyen TLH, et al. Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation. BMC Nephrol. 2023;24(1):131. doi:10.1186/s12882-023-03188-0
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003;76(8):1233–1235. doi:10.1097/01.TP.0000090753.99170.89
   PubMed Web of Science ®Google Scholar
• Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007;81(2):228–234. doi:10.1038/sj.clpt.6100039
   PubMed Web of Science ®Google Scholar
• Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011;91(3):300–308. doi:10.1097/TP.0b013e318200e991
   PubMed Web of Science ®Google Scholar
• Nhung VP, Ton ND, Ha NH. Study of CYP3A5 genetic polymorphism in Vietnamese Kinh ethnic group. Acad J Biol. 2020;42(1):1–13.
   Google Scholar
• Xuan NT, Hop VQ, Kien TQ, et al. Frequencies and association of CYP3A5 polymorphism with tacrolimus concentration among renal transplant recipients in Vietnam. Transplant Proc. 2022;54(8):2140–2146. doi:10.1016/j.transproceed.2022.07.009
   PubMed Web of Science ®Google Scholar
• Darwich AS, Polasek TM, Aronson JK, et al. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol. 2021;61(1):225–245. doi:10.1146/annurev-pharmtox-033020-113257
   PubMed Web of Science ®Google Scholar
• Sarasamma S, Gracious N, Nair S, Radhakrishnan R. Pharmacogenomics of CYP3A5 polymorphism: predicting dose-adjusted trough levels of tacrolimus in south Indian renal transplant patients. J Pharmacogenomics Pharmacoproteomics. 2016;7(161):2.
   Google Scholar
• Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models. In: Chapter 8: Introduction to Model Evaluation. John Wiley & Sons, Inc; 2014:212–217.
   Google Scholar
• Methaneethorn J, Lohitnavy M, Onlamai K, Leelakanok N. Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients. Eur J Drug Metab Pharmacokinet. 2022;47(1):105–116. doi:10.1007/s13318-021-00735-8
   PubMed Web of Science ®Google Scholar
• Han N, Yun HY, Hong JY, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53–63. doi:10.1007/s00228-012-1296-4
   PubMed Web of Science ®Google Scholar
• Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017;42(4):425–432. doi:10.1111/jcpt.12523
   PubMed Web of Science ®Google Scholar
• Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71(3):391–402. doi:10.1111/j.1365-2125.2010.03837.x
   PubMed Web of Science ®Google Scholar
• Zhu W, Xue L, Peng H, et al. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients. Pharmacogenomics. 2018;19(13):1013–1025. doi:10.2217/pgs-2017-0139
   PubMed Web of Science ®Google Scholar
• Ling J, Dong LL, Yang XP, et al. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. Xenobiotica. 2020;50(12):1501–1509. doi:10.1080/00498254.2020.1774682
   PubMed Web of Science ®Google Scholar
• Chauhan PM, Hemani RJ, Solanki ND, et al. A systematic review and meta-analysis recite the efficacy of Tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene. Am J Clin Exper Urol. 2023;11(4):275–292.
   PubMed Web of Science ®Google Scholar
• Khan AR, Raza A, Firasat S, Abid A. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis. Pharmacogen J. 2020;20(4):553–562. doi:10.1038/s41397-019-0144-7
   PubMed Web of Science ®Google Scholar
• Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72(6):660–669. doi:10.1067/mcp.2002.129304
   PubMed Web of Science ®Google Scholar
• Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64(6):750–757. doi:10.1111/j.1365-2125.2007.02888.x
   PubMed Web of Science ®Google Scholar
• Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307. doi:10.1097/FTD.0000000000000640
   PubMed Web of Science ®Google Scholar
• Zhao CY, Jiao Z, Mao JJ, Qiu XY. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81(5):891–907. doi:10.1111/bcp.12830
   PubMed Web of Science ®Google Scholar